Evaluation of 1cp-LSD for Enhancing Welfare in Shelter Dogs: A Randomized Blind Trial with Ethological Intervention.

Giving shelter dogs a low dose of 1cp-LSD (a legal LSD-like compound) alongside behavioral therapy improves their sociability, calmness, and positive emotional reactivity more than either treatment alone. Twenty dogs were randomly assigned to receive the drug, ethological intervention, both, or neither. The combined treatment produced benefits that lasted for three weeks after the sessions ended. These results offer early evidence that integrating low-dose psychedelics with behavioral therapy could help reduce stress and anxiety in shelter dogs, though larger studies are needed to confirm safety and effectiveness.

Study at a glance

Abstract

Shelter environments frequently expose dogs to chronic stress and anxiety, which can compromise their welfare and reduce their chances of adoption. Recent interest in psychedelic-assisted approaches has suggested potential therapeutic applications in veterinary behavioral medicine, although empirical evidence remains scarce. This study aimed to evaluate the combined effects of low-dose 1-cyclopropionyl lysergic acid diethylamide (1cp-LSD), a legal lysergamide prodrug of LSD in several countries, and ethological intervention (EI) on the behavior and welfare of shelter dogs. Twenty dogs were randomly assigned to four groups: pharmacological intervention, ethological intervention, combined treatment, or control. The ethological sessions were conducted by veterinary behaviorists, and pharmacological treatment consisted of 10 µg of 1cp-LSD administered orally for three weeks. Blinded evaluators assessed animals using validated anxiety and welfare scales, including a treatment expectation scale, before, during and after the intervention. Results showed that the combined condition consistently outperformed single interventions, significantly enhancing sociability, calmness, and positive emotional reactivity. Importantly, these improvements persisted for three weeks following treatment cessation, indicating sustained benefits beyond the active intervention phase. These findings provide preliminary evidence for the potential of integrating low doses of psychedelics with behavioral therapy in shelter settings. Future studies with larger cohorts and refined pharmacokinetic data are required to confirm safety, elucidate mechanisms, and optimize protocols for clinical application in veterinary practice.